Ketamine as an Analgesic Adjunct for Opioid-Induced Hyperalgesia in a Patient With a Sickle Cell Pain Episode

REFERENCES

1. 1.↵
   1. Uwaezuoke SN,
   2. Ayuk AC,
   3. Ndu IK,
   4. Eneh CI,
   5. Mbanefo NR,
   6. Ezenwosu OU

   . Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management. J Pain Res. 2018;11:3141-3150. doi: 10.2147/JPR.S185582

   OpenUrlCrossRef
2. 2.↵
   1. Lee M,
   2. Silverman SM,
   3. Hansen H,
   4. Patel VB,
   5. Manchikanti L

   . A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145-161.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. Neri CM,
   2. Pestieau SR,
   3. Darbari DS

   . Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease. Paediatr Anaesth. 2013;23(8):684-689. doi: 10.1111/pan.12172

   OpenUrlCrossRef
4. 4.↵
   1. Brandow AM,
   2. Carroll CP,
   3. Creary S,
   4. et al.

   American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656-2701. doi: 10.1182/bloodadvances.2020001851

   OpenUrlCrossRefPubMed
5. 5.↵
   1. van Beers EJ,
   2. van Tuijn CF,
   3. Nieuwkerk PT,
   4. Friederich PW,
   5. Vranken JH,
   6. Biemond BJ

   . Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. Am J Hematol. 2007;82(11):955-960. doi: 10.1002/ajh.20944

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Yawn BP,
   2. Buchanan GR,
   3. Afenyi-Annan AN,
   4. et al.

   Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published correction appears in JAMA. 2014 Nov 12;312(18):1932] [published correction appears in JAMA. 2015 Feb 17;313(7):729]. JAMA. 2014;312(10):1033-1048. doi: 10.1001/jama.2014.10517

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Schwenk ES,
   2. Viscusi ER,
   3. Buvanendran A,
   4. et al.

   Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):456-466. doi: 10.1097/AAP.0000000000000806

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Subramaniam K,
   2. Subramaniam B,
   3. Steinbrook RA

   . Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg. 2004;99(2):482-495. doi: 10.1213/01.ANE.0000118109.12855.07

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Jouguelet-Lacoste J,
   2. La Colla L,
   3. Schilling D,
   4. Chelly JE

   . The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature. Pain Med. 2015;16(2):383-403. doi: 10.1111/pme.12619

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Chazan S,
    2. Ekstein MP,
    3. Marouani N,
    4. Weinbroum AA

    . Ketamine for acute and subacute pain in opioid-tolerant patients. J Opioid Manag. 2008;4(3):173-180. doi: 10.5055/jom.2008.0023

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Strickler EM,
    2. Schwenk ES,
    3. Cohen MJ,
    4. Viscusi ER

    . Use of ketamine in a multimodal analgesia setting for rapid opioid tapering in a profoundly opioid-tolerant patient: a case report. A A Pract. 2018;10(7):179-181. doi: 10.1213/XAA.0000000000000653

    OpenUrlCrossRef
12. 12.↵
    1. Palm N,
    2. Floroff C,
    3. Hassig TB,
    4. Boylan A,
    5. Kanter J

    . Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: a case series. J Pain Palliat Care Pharmacother. 2018;32(1):20-26. doi: 10.1080/15360288.2018.1468383

    OpenUrlCrossRef
13. 13.↵
    1. Uprety D,
    2. Baber A,
    3. Foy M

    . Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature. Ann Hematol. 2014;93(5):769-771. doi: 10.1007/s00277-013-1954-3

    OpenUrlCrossRef
14. 14.↵
    1. Nielsen S,
    2. Degenhardt L,
    3. Hoban B,
    4. Gisev N

    . A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. Pharmacoepidemiol Drug Saf. 2016;25(6):733-737. doi: 10.1002/pds.3945

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Wesson DR,
    2. Ling W

    . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-259. doi: 10.1080/02791072.2003.10400007

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Simons LE,
    2. Elman I,
    3. Borsook D

    . Psychological processing in chronic pain: a neural systems approach. Neurosci Biobehav Rev. 2014;39:61-78. doi: 10.1016/j.neubiorev.2013.12.006

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Powell RE,
    2. Lovett PB,
    3. Crawford A,
    4. et al.

    A multidisciplinary approach to impact acute care utilization in sickle cell disease. Am J Med Qual. 2018;33(2):127-131. doi: 10.1177/1062860617707262

    OpenUrlCrossRef
18. 18.↵
    1. Chang P,
    2. Chan KE,
    3. Ganendran A

    . Cardiovascular effects of 2-(O-chlorophenyl)-2-methylaminocyclohexanone (CI-581) in rats. Br J Anaesth. 1969;41(5):391-395. doi: 10.1093/bja/41.5.391

    OpenUrlCrossRefPubMed
19. 19.
    1. Baraka A,
    2. Harrison T,
    3. Kachachi T

    . Catecholamine levels after ketamine anesthesia in man. Anesth Analg. 1973;52(2):198-200.

    OpenUrlPubMedWeb of Science
20. 20.↵
    1. López-Gil X,
    2. Jiménez-Sánchez L,
    3. Campa L,
    4. Castro E,
    5. Frago C,
    6. Adell A

    . Role of serotonin and noradrenaline in the rapid antidepressant action of ketamine. ACS Chem Neurosci. 2019;10(7):3318-3326. doi: 10.1021/acschemneuro.9b00288

    OpenUrlCrossRef